Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-08
2005-02-08
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S248000, C514S249000, C514S252100, C514S255060, C544S336000, C544S338000, C544S353000, C544S354000, C544S356000, C544S349000
Reexamination Certificate
active
06852712
ABSTRACT:
This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56lcktyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
REFERENCES:
patent: 3272824 (1966-09-01), Ebetino et al.
patent: 4661499 (1987-04-01), Young et al.
patent: 5120348 (1992-06-01), Davis et al.
patent: 5319102 (1994-06-01), Davis et al.
patent: 5336518 (1994-08-01), Narayanan et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5474973 (1995-12-01), Davis et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 5605696 (1997-02-01), Eury et al.
patent: 5637113 (1997-06-01), Tartaglia et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5650514 (1997-07-01), Stoltefuss et al.
patent: 5700286 (1997-12-01), Tartaglia et al.
patent: 5700823 (1997-12-01), Hirth et al.
patent: 5760066 (1998-06-01), Tang
patent: 5795889 (1998-08-01), Spada et al.
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 6057320 (2000-05-01), Spada et al.
patent: 6180632 (2001-01-01), Myers et al.
patent: 6528526 (2003-03-01), Myers et al.
patent: 2913728 (1980-10-01), None
patent: 23785 (1981-02-01), None
patent: 0 026 622 (1981-04-01), None
patent: 0 065 287 (1982-11-01), None
patent: 72070 (1983-02-01), None
patent: 0 293 071 (1988-11-01), None
patent: 662473 (1995-07-01), None
patent: 9220642 (1992-11-01), None
patent: 9515758 (1995-06-01), None
patent: 9519169 (1995-07-01), None
patent: 9521613 (1995-08-01), None
patent: 9524190 (1995-09-01), None
patent: 9620191 (1996-07-01), None
patent: 9803505 (1998-01-01), None
patent: WO 9854156 (1998-12-01), None
patent: 9854157 (1998-12-01), None
patent: 9854158 (1998-12-01), None
patent: 0031051 (2000-06-01), None
Chemical Abstract DN 95:25134, also cited as EP 23785.*
Chemical Abstract DN 106: 19938, also cited as Dyes & Pigments, 7/6, 445-55 (1986).*
Cecill Textbook of Medicine, 20thEdn., vol. 1, pp. 1005-1010(1996).*
Uckum et al, Current Cancer Drug Targets, 1, 59-71 (2001).*
Lu et al, PubMed Abstract 12247698, also cited as Oncogene. 21/54,8347-50(2002).*
Singer et al, PubMed Abstract 12040176, also cited as Science, 296/5573, 1639-40(2002).*
Kreettek et al, PubMed Abstract 11395922, also cited as Atherosclerosis. 156/2, 267-75(2001).*
Kaminski et al, PubMed Abstract 11264163, also cited as Blood, 97/7, 1990-8(2001).*
Le Guillanton et al., “Electrogenerated Electrophilic Reagents from Sulpher: A New Access to Bis-methoxyaryl Sulphides,” Chem. Commun., 5:393-394 (1990).
Santangelo et al., “Synthesis & Positive Inotropic Effect . . . ”,Eur. J. Med. Chem.(1994), 29:877-82.
Zeller et al., “Synthe. V. Chinoxaline-Derv.”,Helv. Chim. Acta(1966), 49: 913-939.
Makino et al.,Nippon Noyaku Gakkaishi.(1986), 11: 469-72.
Maguire et al., A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Subtituted Quinoline Derivatives, J. Med. Chem., 1994, 37, 2129-2137.
Preparation of 3-(N-aryl-and N-heterocyclaminomethyl) indole derivatives having excellent effect . . . nerve growth factor, Chem. Abstracts, vol. 125, No. 15, 1996, p. 1213, Col. 2, No. 195667C.
Rice et al., Specific Inhibitors of Platelet-Derived Growth Factor of Epidermal Growth Factor Receptor Tyrosine Kinase Reduce Pulmonary Fibrosis in Rats, Am. J. Pathol., 1999, 155(a), pps. 213-221.
Heldin et al., Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor, Physiological Reviews, 199, 79(4), pps. 1283-1316.
Loriga et al., Quinoxaline Chemistry, Part 4, 2-(R)-Anilinoquinoxalines as Nonclassical Antifolate Agents., Il Famaco, 50(5); 289-301 (1995).
Kim et al., A Selective Synthesis of Isoxazolo [2,3-1] quinoxalines and Pyrrolo [1,2-a]quinoxalines by 1,3-Dipolar Cycloaddition Reaction, Journal of the Korean Chemical Society, vol. 34, No. 5, 1990, pp. a469-475.
Rewcastle et al., Tyrosine Kinase Inhibitors, J. Med. Chem. 1995, 38, 3482-3487.
Newbold et al., The Oxidation of 2-Hydroxyquinoxaline and its Derivatives with Hydrogen Peroxide, J. Chem Soc., 1948 (519-522).
Makino et al., They Synthesis of Novel 2-(2-Quinoxalinyl) Pyridazine-3(2H)-Ones, Heterocycles, vol. 23, No. 10, 1985, pp. 2603-2611.
Burke, Jr., Protein-Tyrosine Kinases: Potential Targets for Anti-cancer Drug Development, Stem Cells, 1994; 12:1-6.
N-Quinoxalinylanilines, Chemical Abstracts, vol. 103, 1985, 106539f.
Lin et al., Studies on antiarrhythmics, Chemical Abstracts, vol. 96, 1982, 122728w.
Takase et al., Preparation of N-containing heterocyclic compounds as phosphodiesterase inhibitors, Chemical Abstracts, vol. 119, 1993, 203427t.
Hirth et al., Derwent computer search, 1995, 861279.
Hirth et al., Derwent Information Ltd., 1982-64774E.
Hirth et al., Derwent Information Ltd., 1985-168512.
Shawyer et al., Inhibition of Platelet-derived Growth Factor-medicated Signal Transduction and Tumor Growth by N-[4-Trifluoromethyl0-phenyl]5-Methylisoxazole-4carboxamide, Clinical Cancer Research, vol. 3, 1167-1177, Jul. 1997.
Klutchko et al., 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones., J. Med. Chem., 1998, 41, 3276-3292.
Sakata et al., Chem. Abstract, Nippon Noyaku Gakkasishi, 19(1), 61-7, (1985); 104: 109577.
He Wei
Maguire Martin P.
Myers Michael R.
Spada Alfred P.
Aventis Pharmaceuticals Inc.
Patel Sudhaker B.
Shah Mukund J.
Synnestvedt & Lechner LLP
LandOfFree
Quinoline and quinoxaline compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline and quinoxaline compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline and quinoxaline compounds which inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461820